Cite
MLA Citation
Nicole Concin et al.. “2022-RA-459-ESGO UPLIFT (ENGOT-ov67/GOG-3048) a registrational trial of Upifitamab Rilsodotin (XMT-1536; UpRi), a NaPi2b-directed antibody drug conjugate (ADC) in platinum-resistant ovarian cancer.” International journal of gynecological cancer, vol. 32, n.d., p. A237. http://access.bl.uk/ark:/81055/vdc_100168339599.0x000025